Neurocrine (NBIX)
NASDAQ:NBIX
Want to see NBIX full AI Analyst Report?
NBIX Stock Chart & Stats
$133.25
$0.29(0.21%)
At close: 4:00 PM EST
$133.25
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$108.35 - $160.18
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.02M
Market Cap
$13.46B
Enterprise Value$13.16B
Total Cash (Recent Filing)$1.48B
Total Debt (Recent Filing)$415.30M
Price to Earnings (P/E)23.0
Beta0.63
Next Earnings
Aug 04, 2026EPS Estimate
1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.82
Shares Outstanding100,363,464
10 Day Avg. Volume1,270,182
30 Day Avg. Volume1,020,307
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)4.34
Price to Sales (P/S)4.93
P/FCF Ratio18.85
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.60
Enterprise Value/Gross Profit4.69
Enterprise Value/Ebitda18.30
Forecast
1Y Price Target
$183.89Price Target Upside38.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)6.22
Revenue Forecast (FY)$3.48B
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionAnalyst notes Neurocrine Biosciences' established commercial infrastructure and payer relationships could accelerate Vykat XR prescribing among endocrinologists and neurologists, supporting faster revenue diversification away from incumbent products.
Deal Financing And Earnings ImpactManagement states the acquisition is financed mainly from available cash with modest additional debt and is expected to be accretive to revenue and adjusted earnings at closing, making the purchase financially manageable.
Regulatory Exclusivity And Product DifferentiationVykat XR's status as the only approved therapy for severe hyperphagia in Prader-Willi syndrome and an extended intellectual property profile support premium pricing and limited direct competition.
Bears Say
International Market LimitationManagement's decision not to commercialize the drug outside the United States constrains total market opportunity unless an international partner is secured, reducing potential upside.
Launch Disruption And Investor PerceptionA bearish short-seller report combined with an early rocky launch has hurt uptake and could prolong skepticism among prescribers and investors, slowing broader adoption.
Safety And Treatment PersistenceAnalysts warn safety signals such as elevated blood sugar and fluid retention and real-world discontinuation concerns could reduce long-term patient retention and limit prescription growth.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $108.35 and its highest was $160.18 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $13.46B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Aug 04, 2026 which is in 90 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on May 05, 2026. The company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.216 by $0.694.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.41.
How many shares outstanding does Neurocrine have?
Neurocrine has 100,363,464 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.91 in its last earnings report, beating expectations of $1.216. Following the earnings report the stock price went down -10.434%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$183.89 (38.01% Upside)
$183.89 (38.01% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 38.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.43%
12-Months-Change
Fundamentals
Return on Equity
16.67%
Trailing 12-Months
Asset Growth
23.56%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Company Deck
NBIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance (record quarterly net product sales, INGREZZA growth of 20% YoY to $657M, Cranesity annualizing >$600M, ~44% overall revenue growth) alongside robust pipeline progress (multiple Phase 1/2 starts in 2026 and key Phase 3 readouts expected in 2027). Minor near-term headwinds were noted, including Q1 gross-to-net pressure for Cranesity, recurring Q1 payer seasonality for INGREZZA, early-stage commercial penetration for Cranesity, and limited disclosure on an in-progress acquisition. Overall, the positive commercial execution, high profitability, and strong R&D momentum materially outweigh the modest operational and timing risks discussed on the call.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$183.89
▲(38.01% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.17% Insiders
26.92% Mutual Funds
2.79% Other Institutional Investors
40.08% Public Companies and Individual Investors